ESR1 and breast carcinoma: The antiarrhythmic agent procainamide, a non-nucleoside DNMT analog, increases the responsiveness of Eα-positive breast cancer cells to the estrogen receptor antagonist, tamoxifen, by increasing ERβ expression [110].